Pharsight

Silenor generic

Silenor is an insomnia treatment drug owned by Currax. It contains the active ingredient doxepin hydrochloride and was authorised for market use on 17 March, 2010. The drug exists in tablet;oral dosage forms. It has a total of 15 drug patents, none of which have expired.

When will Silenor generic be available?

The generic version of Silenor is expected to be released after 07 September, 2030. This date corresponds to the expiry date of the last patent. The potential generics would be able to leverage the effectiveness of Doxepin Hydrochloride in treating insomnia.

Silenor uses

Silenor, which contains doxepin hydrochloride, is primarily used for the treatment of insomnia. The active ingredient aids in regulating sleep rhythms, thus curbing insomnia issues.

Silenor patent expiration

Silenor, owned by Currax, is covered by 15 patents. The patents primarily deal with the utilization of low-dose Doxepin Hydrochloride for the improvement of sleep and the development of optimized formulations. The expiration date of the last patent, implying the prospective availability of Silenor generic, is 07 September, 2030. Below are the details of the patent:

Litigations filed on Silenor

Silenor dosage

Want to ask something?